Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 8/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 6/20 | 0.47 |
| ▸ | PPARD | Q03181 | 6/20 | 0.47 |
| ▸ | PPARA | Q07869 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6352256 | 0.92 | ALB (0.70) | ALBAKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6358241 | 0.90 | ALB (0.64) | ALBTP53LMNASMN1; SMN2THRB | |
| SCHEMBL6357110 | 0.89 | ALB (0.65) | ALBTP53LMNASMN1; SMN2THRB | |
| SCHEMBL6352516 | 0.88 | ALB (0.62) | ALBTP53LMNASMN1; SMN2THRB | |
| SCHEMBL6354039 | 0.84 | TP53 (0.69) | ALBTP53SMN1; SMN2PPARGPPARD | |
| SCHEMBL6359330 | 0.84 | TP53 (0.72) | ALBTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6353328 | 0.83 | ALB (0.81) | ALBTP53THRBMEN1KMT2A | |
| SCHEMBL6358764 | 0.83 | TP53 (0.71) | ALBTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6350731 | 0.83 | TP53 (0.71) | ALBTP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6352302 | 0.83 | ALB (0.59) | ALBTP53KMT2APPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2005-05-26 | — | — | US | claimed |
| WO-2004018414-A2 | ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | CLPP, SPOUT1, SAMHD1 | ALB 1682/4885TP53 2308/4885SIRT2 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.